Skip to search formSkip to main contentSkip to account menu

insulin degludec

Known as: (1A-21A),(1B-29B)-insulin (human), 29B-(N6-(N-(15-carboxy-1- oxopentadecyl)-L-gamma- glutamyl)-L-lysine)-, INSULIN,DEGLUDEC,HUMAN/RDNA, degludec 
National Institutes of Health

Related topics

Related topics

13 relations
3 ML insulin degludec 200 UNT/ML Pen Injector3 ML insulin degludec 200 UNT/ML Pen Injector [Tresiba]Decreased Lipolysis [PE]Diabetes Mellitus, Insulin-Dependent

Broader (1)

Insulin, Long-Acting

Narrower (1)

Xultophy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
To compare day‐to‐day and within‐day variability in glucose‐lowering effect between insulin degludec (IDeg) and insulin glargine… 
Highly Cited
2015
Highly Cited
2015
One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial
To confirm, in a 26‐week extension study, the sustained efficacy and safety of a fixed combination of insulin degludec and… 
Highly Cited
2015
Highly Cited
2015
Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
Insulin degludec (IDeg) once‐daily was compared with insulin detemir (IDet) once‐ or twice‐daily, with prandial insulin aspart in… 
Review
2014
Review
2014
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Insulin degludec (IDeg) is a new-generation basal insulin with an ultra-long duration of action. To date, a large number of… 
Highly Cited
2014
Highly Cited
2014
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)
Two treatment strategies were compared in patients with type 2 diabetes (T2DM) on basal insulin requiring intensification… 
Highly Cited
2013
Highly Cited
2013
Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial
Insulin degludec (IDeg) is an ultra‐long‐acting basal insulin with a consistent action profile of >42 h. This trial compared the… 
Highly Cited
2013
Highly Cited
2013
The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily
OBJECTIVE The requirement to inject current basal insulin analogs at a fixed time each day may complicate adherence and… 
Highly Cited
2012
Highly Cited
2012
Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Insulin degludec (IDeg) is a new‐generation, ultra‐long‐acting basal insulin that forms soluble multihexamers upon subcutaneous… 
Highly Cited
2011
Highly Cited
2011
Insulin Degludec in Type 1 Diabetes
OBJECTIVE Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in… 
Highly Cited
1995
Highly Cited
1995
Flow cytometric analysis for cytokine production identifies T helper 1, T helper 2, and T helper 0 cells within the human CD4+CD27- lymphocyte subpopulation.
Using three-color flow cytometric analysis for the detection of intracellular cytokines, we have been able to determine the exact… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)